Junctional and somatic hypermutation-induced CX4C motif is critical for the recognition of a highly conserved epitope on HCV E2 by a human broadly neutralizing antibody

[1]  J. Bukh,et al.  Genetic and structural insights into broad neutralization of hepatitis C virus by human VH1-69 antibodies , 2019, Science Advances.

[2]  J. Bukh,et al.  Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms , 2018, Journal of Virology.

[3]  James E Crowe,et al.  HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. , 2018, Cell host & microbe.

[4]  G. Learn,et al.  Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. , 2018, Cell host & microbe.

[5]  J. Mascola,et al.  HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure. , 2018, Immunity.

[6]  A. Cox,et al.  Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine? , 2018, Trends in Microbiology.

[7]  M. Buti,et al.  Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. , 2017, Gastroenterology.

[8]  Immunogenetic factors driving formation of ultralong VH CDR3 in Bos taurus antibodies , 2018, Cellular & Molecular Immunology.

[9]  James E Crowe,et al.  Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms , 2017, Proceedings of the National Academy of Sciences.

[10]  Johnathan D. Guest,et al.  Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis , 2017, PLoS pathogens.

[11]  Qiang Sun,et al.  A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey , 2017, Gut.

[12]  G. Learn,et al.  Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. , 2017, JCI insight.

[13]  K. Chayama,et al.  Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV , 2017, Expert review of clinical pharmacology.

[14]  B. Pierce,et al.  Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design , 2016, Proceedings of the National Academy of Sciences.

[15]  Zhong Huang,et al.  Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice , 2016, Journal of Virology.

[16]  J. Niu,et al.  IFN-λ4 desensitizes the response to IFN-α treatment in chronic hepatitis C through long-term induction of USP18. , 2016, The Journal of general virology.

[17]  B. Pierce,et al.  Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies , 2016, Expert review of vaccines.

[18]  J. Niu,et al.  Interferon alpha (IFNα)-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A , 2015, Cellular and Molecular Immunology.

[19]  H. Drummer,et al.  Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region , 2015, Journal of Virology.

[20]  D. Dimitrov,et al.  Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody , 2015, Nature Communications.

[21]  David Nemazee,et al.  Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen , 2015, Science.

[22]  S. Ray,et al.  Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses , 2014, Hepatology.

[23]  Thomas F. Baumert,et al.  Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents , 2014, PLoS pathogens.

[24]  Anneliese O. Speak,et al.  Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery , 2014, Nature Biotechnology.

[25]  R. Sanders,et al.  Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development? , 2014, Expert review of vaccines.

[26]  S. Levy,et al.  CD81 and Hepatitis C Virus (HCV) Infection , 2014, Viruses.

[27]  Robyn L. Stanfield,et al.  Hepatitis C Virus E2 Envelope Glycoprotein Core Structure , 2013, Science.

[28]  Jin Zhong,et al.  A Novel Strategy To Develop a Robust Infectious Hepatitis C Virus Cell Culture System Directly from a Clinical Isolate , 2013, Journal of Virology.

[29]  N. Zhang,et al.  Construction and characterization of infectious hepatitis C virus chimera containing structural proteins directly from genotype 1b clinical isolates. , 2013, Virology.

[30]  Peter G. Schultz,et al.  Reshaping Antibody Diversity , 2013, Cell.

[31]  P. Klenerman,et al.  Ever closer to a prophylactic vaccine for HCV , 2013, Expert opinion on biological therapy.

[32]  A. Meola,et al.  Structural Basis of HCV Neutralization by Human Monoclonal Antibodies Resistant to Viral Neutralization Escape , 2013, PLoS pathogens.

[33]  Bian-Li Xu,et al.  Fully human broadly neutralizing monoclonal antibodies against influenza A viruses generated from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient , 2012, Virology.

[34]  I. Wilson,et al.  Structure of Hepatitis C Virus Envelope Glycoprotein E2 Antigenic Site 412 to 423 in Complex with Antibody AP33 , 2012, Journal of Virology.

[35]  Charles M. Rice,et al.  Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus , 2012, Proceedings of the National Academy of Sciences.

[36]  A. Tarr,et al.  Naturally Occurring Antibodies That Recognize Linear Epitopes in the Amino Terminus of the Hepatitis C Virus E2 Protein Confer Noninterfering, Additive Neutralization , 2011, Journal of Virology.

[37]  M. Hiet,et al.  Mouse hepatic cells support assembly of infectious hepatitis C virus particles. , 2011, Gastroenterology.

[38]  G. Szabo,et al.  Identification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C Virus , 2009, Journal of Virology.

[39]  Q. Hu,et al.  Specifically Binding of L-ficolin to N-glycans of HCV Envelope Glycoproteins E1 and E2 Leads to Complement Activation , 2009, Cellular and Molecular Immunology.

[40]  A. Bergman,et al.  V-region mutation in vitro, in vivo, and in silico reveal the importance of the enzymatic properties of AID and the sequence environment , 2009, Proceedings of the National Academy of Sciences.

[41]  D. Burton,et al.  Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge , 2008, Nature Medicine.

[42]  D. Burton,et al.  Robust hepatitis C virus infection in vitro. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Pawlotsky.  Pathophysiology of hepatitis C virus infection and related liver disease. , 2004, Trends in microbiology.

[44]  H. Nakamura,et al.  Junctional amino acids determine the maturation pathway of an antibody. , 1999, Immunity.